CSL Behring Launches Co-Pay Assistance Program For Berinert
This article was originally published in The Pink Sheet Daily
Executive Summary
Program provides commercially insured patients with up to $12,000 a year in eligible expenses for C1 esterase inhibitor Berinert, used to treat the rare disease hereditary angioedema.